Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy.

Keisho Chin,Ken Kato,Byoung Chul Cho,Masanobu Takahashi,Morihito Okada,Chen Yuan Lin,Shigenori Kadowaki,Myung-Ju Ahn,Yasuo Hamamoto,Yuichiro Doki,Chueh-Chuan Yen,Yutaro Kubota,Sung-Bae Kim,Chih-Hung Hsu,Eva Holtved,Ioannis Xynos,Yasuhiro Matsumura,Akira Takazawa,Yuko Kitagawa

Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy.

2021

Keisho Chin
Ken Kato
Byoung Chul Cho
Masanobu Takahashi
Morihito Okada
Chen Yuan Lin
Shigenori Kadowaki
Myung-Ju Ahn
Yasuo Hamamoto
Yuichiro Doki
Chueh-Chuan Yen
Yutaro Kubota
Sung-Bae Kim
Chih-Hung Hsu
Eva Holtved
Ioannis Xynos
Yasuhiro Matsumura
Akira Takazawa
Yuko Kitagawa

204Background: Previous results from the ATTRACTION-3 phase 3 trial demonstrated a significant improvement in overall survival and a favorable safety profile compared with taxane chemotherapy (CT) ...

Keywords:

esophageal squamous cell carcinoma
Refractory
Oncology
overall survival
Nivolumab
Internal medicine
in patient
Chemotherapy
Taxane
safety profile
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations